---
document_datetime: 2026-01-20 12:38:03
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/poteligeo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: poteligeo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9191001
conversion_datetime: 2026-01-22 21:25:11.964467
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## POTELIGEO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 20/01/2026                          | N/A                                         |                                  | To update the RMP by revising the status, |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000320532                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To update the RMP by revising the status, objectives, and study milestones in accordance with the updated and approved protocol for the Category 3 PASS study: 'Post-authorisation safety study of allogeneic hematopoietic cell transplantation in patients treated with mogamulizumab.' The due date for the final study report has been changed from July 2024 to March 2029. Additionally, the MAH is updating the RMP to reflect the current Data Lock Point (29 March 2025) and to align with the RMP template (Module V   |            |     | objectives, and study milestones in accordance with the updated and approved protocol for the Category 3 PASS study: 'Post-authorisation safety study of allogeneic hematopoietic cell transplantation in patients treated with mogamulizumab.' The due date for the final study report has been changed from July 2024 to March 2029. Additionally, the MAH is updating the RMP to reflect the current Data Lock Point (29 March 2025) and to align with the RMP template (Module V Rev.2.0.1).   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000315552 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/12/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Variation type IB / EMA/VR/0000314958 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/12/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                          | Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |             |                                                                                                            |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000281781    | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.b Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - Accepted | 17/07/2025 | N/A |             |                                                                                                            |
| Variation type IA_IN / EMA/VR/0000273196 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                                                  | 21/05/2025 |     | SmPC and PL | To update section 4.8 of the SmPC and section 4 of the PL following the PRAC signal assessment for colitis |